← All trials
NCT04694300
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2021
- Primary completion
- Jan 19, 2022
- Completion date
- Jan 19, 2022
- First posted
- Jan 5, 2021
- Last posted
- Jan 5, 2021
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hersh, Elliot V., DMD, MS, PhDLead sponsor
- University of PennsylvaniaOverall official - principal investigator
- University of PennsylvaniaCollaborator
- BayerCollaborator
- University of PennsylvaniaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.